Key result
Elevated hs-cTnT linked to ~96% higher risk of cardiovascular events in diabetes.
Why the study?
Does the addition of NTproBNP and high-sensitivity troponin T improve cardiovascular risk prediction beyond traditional markers in patients with diabetes?
Observational (n=1,510)
Yes
Does the addition of NTproBNP and high-sensitivity troponin T improve cardiovascular risk prediction beyond traditional markers in patients with diabetes?
Elevated NTproBNP and high-sensitivity troponin T significantly improve cardiovascular risk stratification in patients with diabetes beyond traditional risk factors.
May enhance risk stratification in diabetes; extends observational data but leaves open whether adoption improves outcomes.
OBJECTIVE: Cardiovascular disease (CVD) is the major cause of morbidity and mortality in diabetes; yet, heterogeneity in CVD risk has been suggested in diabetes, providing a compelling rationale for improving diabetes risk stratification. We hypothesized that N-terminal prohormone brain natriuretic peptide (NTproBNP) and high-sensitivity troponin T may enhance CVD risk stratification beyond commonly used markers of risk and that CVD risk is heterogeneous in diabetes. RESEARCH DESIGN AND METHODS: Among 8,402 participants without prevalent CVD at visit 4 (1996-1998) of the Atherosclerosis Risk in Communities (ARIC) study there were 1,510 subjects with diabetes (mean age 63 years, 52% women, 31% African American, and 60% hypertensive). RESULTS: Over a median follow-up of 13.1 years, there were 540 incident fatal/nonfatal CVD events (coronary heart disease, heart failure, and stroke). Both troponin T ≥14 ng/L (hazard ratio [HR] 1.96 [95% CI 1.57-2.46]) and NTproBNP >125 pg/mL (1.61 [1.29-1.99]) were independent predictors of incident CVD events at multivariable Cox proportional hazard models. Addition of circulating cardiac biomarkers to traditional risk factors, abnormal electrocardiogram (ECG), and conventional markers of diabetes complications including retinopathy, nephropathy, and peripheral arterial disease significantly improved CVD risk prediction (net reclassification index 0.16 [95% CI 0.07-0.22]). Compared with individuals without diabetes, subjects with diabetes had 1.6-fold higher adjusted risk of incident CVD. However, participants with diabetes with normal cardiac biomarkers and no conventional complications/abnormal ECG (n = 725 [48%]) were at low risk (HR 1.12 [95% CI 0.95-1.31]), while those with abnormal cardiac biomarkers, alone (n = 186 [12%]) or in combination with conventional complications/abnormal ECG (n = 243 [16%]), were at greater risk (1.99 [1.59-2.50] and 2.80 [2.34-3.35], respectively). CONCLUSIONS: Abnormal levels of NTproBNP and troponin T may help to distinguish individuals with high diabetes risk from those with low diabetes risk, providing incremental risk prediction beyond commonly used markers of risk.
No takes yet. Share an insight, caveat, or question.
Gori et al. (2016) conducted an observational in Diabetes without prevalent cardiovascular disease (n=1,510). Elevated high-sensitivity troponin T (≥14 ng/L) vs. Normal high-sensitivity troponin T (<14 ng/L) was evaluated on Incident fatal or nonfatal cardiovascular events (coronary heart disease, heart failure, and stroke) (HR 1.96, 95% CI 1.57-2.46, p=<0.05). Elevated levels of high-sensitivity troponin T (HR 1.96) and NTproBNP (HR 1.61) were independent predictors of incident cardiovascular events in individuals with diabetes, significantly improving risk reclassification beyond traditional markers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: